The largest program at SMRI is for the identification of medications that will improve the treatment of schizophrenia and bipolar disorder. Although medications have been available since the 1960s, they have proven to be only partially effective. Many individuals affected with these diseases continue to have symptoms even when taking available medications, while others find it difficult to take medications because of side effects.
The purpose of this program is to support the testing of medications to assess their efficacy for treating schizophrenia and bipolar disorder. At any given time, SMRI is supporting 50-60 treatment trials, the majority of which are generic and/or off-label medications.
SMRI has suspended open calls for submissions at this time. SMRI is committed to funding additional studies in the future, but they may be done as a specific call to study certain compounds. A notification will be posted when the next application cycle is known, and an email alert will be sent to all past grantees. If you wish to receive an email alert, please email Jana Bowcut at email@example.com.
Drugs that are currently being investigated by SMRI, and those that have been funded in the past are on the List of Awarded Treatment Trials.
Do you have an ongoing trial with SMRI? Please submit your quarterly report here. Please note that quarterly reports are due April 15, July 15 and October 15
Do You Need to Access Past Applications and Quarterly Reports from our Old Website?
Please login here to review past submissions. SMRI does not retain usernames and passwords from the old website.